This company has shut down. Ermium Therapeutics is no longer operating — its last tracked round was a Series A in 2022.
Explore the Startup GraveyardErmium Therapeutics is a biotech company developing innovative therapies for auto-immune diseases.
Ermium Therapeutics has raised $6.3M in total funding. The most recent round was Series A. The last funding was announced in June 2022.
Ermium Therapeutics's investors include Kurma Partners, Eurazeo, Idinvest Partners, Kainova Therapeutics, Fountain Healthcare Partners.
Ermium Therapeutics is headquartered in Paris, France.
Ermium Therapeutics is a biotech company developing innovative therapies for auto-immune diseases.
Ermium Therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Ermium Therapeutics — Funding & Investors." VCBacked, June 30, 2022, https://www.vcbacked.co/company/ermium-therapeutics. Accessed October 8, 2026.
VCBacked. (2022). Ermium Therapeutics — Funding & Investors. Retrieved October 8, 2026, from https://www.vcbacked.co/company/ermium-therapeutics
{{cite web |title=Ermium Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/ermium-therapeutics |website=VCBacked |access-date=October 8, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated